<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336115">
  <stage>Registered</stage>
  <submitdate>21/10/2010</submitdate>
  <approvaldate>2/12/2010</approvaldate>
  <actrnumber>ACTRN12610001063000</actrnumber>
  <trial_identification>
    <studytitle>Early detection and echocardiographic assessment of diabetic heart disease and the impact of neurohormonal inhibition</studytitle>
    <scientifictitle>Echocardiographic assessment and early detection of heart muscle disease in patients with type II diabetes and the impact of neurohormonal inhibition compared with placebo on heart function</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type II diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Eligible patients (about 130 patients) with type II diabetes mellitus with stable metabolic control will be randomised to elperenone or matching placebo. Initial dose will be one tablet a day orally (25 mg).  The dose may be up titrated to 50 mg daily after 4 weeks if the lower dose is tolerated. All patients will be monitored regularly for side effects and blood tests will be obtained to monitor serum electrolytes levels and renal function. Treatment will be maintained for a minimum of 12 months. Heart muscle function and degree of scarring will be assessed with echocardiography at baseline and again at 12 months. Biomarkers levels of collagen synthesis will be assessed at baseline and at 12 months</interventions>
    <comparator>Oral placebo (lactose based pills) once daily for 12 months</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Left ventricular and left atrial function by echocardiogram ultrasound</outcome>
      <timepoint>Patients will be screened on enrolment before randomisation and then 12 month after enrolment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Degree of scarring of the left ventricle and left atrium by echocardiography</outcome>
      <timepoint>Patients will be screened on enrolment before randomisation and then 12 month after enrolment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Biomarkers of collagen synthesis</outcome>
      <timepoint>At baseline and at 12 months after enrolment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type II diabetes mellitus
Stable metabolic control</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Severe heart failure
Chronic kidney diseases (serum creatinine &gt; 220 umol/L)
Hyperkalaemia (serum potassium &gt; 5 mmol/L)
Addison's disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Eligible patients will be approached by the investigators, informed written consent obtained and patients will then be randomised after initial echocardiogram and blood tests. It is a double blind randomised placebo controlled trial and only the trial pharmacist will be aware of treatment allocation.</concealment>
    <sequence>Randomisation will be achieved using a permuted blocks design.  Centralised randomisation will occur via a password protected computer program.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2011</anticipatedstartdate>
    <actualstartdate>2/11/2011</actualstartdate>
    <anticipatedenddate>31/12/2014</anticipatedenddate>
    <actualenddate>23/03/2015</actualenddate>
    <samplesize>130</samplesize>
    <actualsamplesize>140</actualsamplesize>
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Liverpool Hospital - Liverpool</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Liverpool Hospital</primarysponsorname>
    <primarysponsoraddress>Elizabeth Street,
Liverpool, NSW 2170</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>No secondary sponsor</sponsorname>
      <sponsoraddress>No secondary sponsor</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose is to assess the ability of new techniques of echocardiographic assessment of heart function in detecting early heart disease in patients with type II diabetes mellitus and to assess the impact of 12 month period of neurohormonal inhibition in improving heart muscle function and degree of scarring in these patients</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney Southwest Area Health Service Human Research Ethics Committee, Concord Repatriation Hospital</ethicname>
      <ethicaddress>Concord Hospital
Concord, NSW, 2139</ethicaddress>
      <ethicapprovaldate>20/08/2010</ethicapprovaldate>
      <hrec>HREC/10/CRGH/62</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Dominic Leung</name>
      <address>Department of Cardiology
Elizabeth Street
Liverpool Hospital
Liverpool, NSW 2170</address>
      <phone>+61 2 87383797</phone>
      <fax>+61 2 8733054</fax>
      <email>d.leung@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Professor Dominic Leung</name>
      <address>Department of Cardiology
Elizabeth Street
Liverpool Hospital
Liverpool, NSW 2170</address>
      <phone>+61 2 87383797</phone>
      <fax>+61 2 87383054</fax>
      <email>d.leung@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Dominic Leung</name>
      <address>Department of Cardiology
Elizabeth Street
Liverpool Hospital
Liverpool, NSW 2170</address>
      <phone>+61 2 87383797</phone>
      <fax>+61 2 87383054</fax>
      <email>d.leung@unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Dominic Leung</name>
      <address>Department of Cardiology, Liverpool Hospital, Liverpool, NSW 2170</address>
      <phone>+61287383797</phone>
      <fax />
      <email>d.leung@unsw.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>